CD44 and breast carcinoma: Due to its more restricted expression compared with other CSC markers such as CD44 and aldehyde dehydrogenase (ALDH), CD133 has long been considered the most rigorous indicator of malignant precursors in different solid tumors, including breast cancer [14].